James P. Allison, PhD

James P. Allison, PhD, discusses his experience with the urgency of drug development in oncology. 

James P. Allison, PhD, discusses the impact of immunotherapy on patients with cancer. 

James P. Allison, PhD, discusses the development of ipilimumab.

James P. Allison, PhD, discusses his early career at The University of Texas MD Anderson Cancer Center.

James P. Allison, PhD, discusses his research on reverse translation in cancer. 

James P. Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the future of immunotherapy in the treatment of patients with cancer.

James Allison, chair of Immunology at the University of Texas MD Anderson Cancer Center, discusses promising data regarding the use of immunotherapies in melanoma. Allison is particularly excited about a trial, presented at the Society of Melanoma Research Congress, which looked at the combination of PD-L1 inhibitors with a BRAF-targeted agent.

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.